Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study

Paul A. Hamlin, Ian W. Flinn, Nina Wagner-Johnston, Jan A. Burger, Greg P. Coffey, Pamela B. Conley, Glenn Michelson, Janet M. Leeds, Kenneth Der, Yvonne Kim, Alice Sabalvaro-Torres, Matt Birrell, Anjali Pandey, John T. Curnutte, Manish R. Patel

Research output: Contribution to journalLetter

Original languageEnglish (US)
Pages (from-to)E90-E93
JournalAmerican journal of hematology
Volume94
Issue number4
DOIs
StatePublished - Apr 2019

ASJC Scopus subject areas

  • Hematology

Cite this

Hamlin, P. A., Flinn, I. W., Wagner-Johnston, N., Burger, J. A., Coffey, G. P., Conley, P. B., Michelson, G., Leeds, J. M., Der, K., Kim, Y., Sabalvaro-Torres, A., Birrell, M., Pandey, A., Curnutte, J. T., & Patel, M. R. (2019). Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study. American journal of hematology, 94(4), E90-E93. https://doi.org/10.1002/ajh.25387